Apyx Medical initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Apyx Medical (APYX) with a Buy rating and $6 price target The company’s Renuvion technology is the only approved device for treatment of loose skin post liposuction and contracting subcutaneous soft tissue anywhere on the body, the analyst tells investors in a research note. Roth adds that it also expects the U.S. and international adoption will continue to benefit from the broad usage of GLP-1 drugs for weight loss.